Endoscopic ultrasound (EUS) with fine needle aspiration (FNA) adds significant diagnostic specificity in patients with pancreatic cystic neoplasms (PCNs) initially evaluated by MRI.
EUS identifies morphological high-risk features (MHRF) missed by MRI in a subset of patients, which are associated with a substantial upgrade rate for malignancy.
Patients with MHRF detected on MRI but not confirmed by EUS have a high likelihood of remaining cancer-free on surveillance.
Decision-curve analysis highlights the greatest clinical benefit of EUS combined with FNA in patients whose MRI does not reveal MHRF.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
